Compare ABCL & CLOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | CLOV |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2020 | 2020 |
| Metric | ABCL | CLOV |
|---|---|---|
| Price | $5.97 | $4.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $8.40 | $2.90 |
| AVG Volume (30 Days) | ★ 7.5M | 6.9M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.91 | ★ 38.03 |
| EPS | N/A | ★ 0.05 |
| Revenue | $75,128,000.00 | ★ $1,924,308,000.00 |
| Revenue This Year | N/A | $52.59 |
| Revenue Next Year | $21.85 | $15.37 |
| P/E Ratio | ★ N/A | $90.00 |
| Revenue Growth | ★ 160.56 | 40.34 |
| 52 Week Low | $2.75 | $1.58 |
| 52 Week High | $8.44 | $5.59 |
| Indicator | ABCL | CLOV |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 53.27 |
| Support Level | $5.23 | $1.96 |
| Resistance Level | $6.79 | $5.18 |
| Average True Range (ATR) | 0.61 | 0.29 |
| MACD | -0.23 | -0.09 |
| Stochastic Oscillator | 14.66 | 39.18 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.